Weakly-Supervised Classification of HER2 Expression in Breast Cancer Haematoxylin and Eosin Stained Slides

被引:20
|
作者
Oliveira, Sara P. [1 ,2 ]
Pinto, Joao Ribeiro [1 ,2 ]
Goncalves, Tiago [1 ]
Canas-Marques, Rita [3 ,4 ]
Cardoso, Maria-Joao [4 ,5 ]
Oliveira, Helder P. [1 ,6 ]
Cardoso, Jaime S. [1 ,2 ]
机构
[1] INESC TEC, P-4200465 Porto, Portugal
[2] Univ Porto, Fac Engn FEUP, P-4200465 Porto, Portugal
[3] Champalimaud Fdn, Champalimaud Clin Ctr, Anat Pathol Serv, P-1400038 Lisbon, Portugal
[4] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, P-1400038 Lisbon, Portugal
[5] NOVA Med Sch, P-1169056 Lisbon, Portugal
[6] Univ Porto, Fac Sci FCUP, P-4169007 Porto, Portugal
来源
APPLIED SCIENCES-BASEL | 2020年 / 10卷 / 14期
关键词
weakly-supervised learning; HER2; breast cancer; IMAGE-ANALYSIS;
D O I
10.3390/app10144728
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Human epidermal growth factor receptor 2 (HER2) evaluation commonly requires immunohistochemistry (IHC) tests on breast cancer tissue, in addition to the standard haematoxylin and eosin (H&E) staining tests. Additional costs and time spent on further testing might be avoided if HER2 overexpression could be effectively inferred from H&E stained slides, as a preliminary indication of the IHC result. In this paper, we propose the first method that aims to achieve this goal. The proposed method is based on multiple instance learning (MIL), using a convolutional neural network (CNN) that separately processes H&E stained slide tiles and outputs an IHC label. This CNN is pretrained on IHC stained slide tiles but does not use these data during inference/testing. H&E tiles are extracted from invasive tumour areas segmented with the HASHI algorithm. The individual tile labels are then combined to obtain a single label for the whole slide. The network was trained on slides from the HER2 Scoring Contest dataset (HER2SC) and tested on two disjoint subsets of slides from the HER2SC database and the TCGA-TCIA-BRCA (BRCA) collection. The proposed method attained83.3%classification accuracy on the HER2SC test set and 53.8% on the BRCA test set. Although further efforts should be devoted to achieving improved performance, the obtained results are promising, suggesting that it is possible to perform HER2 overexpression classification on H&E stained tissue slides.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] A deep learning framework deploying segment anything to detect pan-cancer mitotic figures from haematoxylin and eosin-stained slides
    Shen, Zhuoyan
    Simard, Mikael
    Brand, Douglas
    Andrei, Vanghelita
    Al-Khader, Ali
    Oumlil, Fatine
    Trevers, Katherine
    Butters, Thomas
    Haefliger, Simon
    Kara, Eleanna
    Amary, Fernanda
    Tirabosco, Roberto
    Cool, Paul
    Royle, Gary
    Hawkins, Maria A.
    Flanagan, Adrienne M.
    Collins-Fekete, Charles-Antoine
    COMMUNICATIONS BIOLOGY, 2024, 7 (01)
  • [22] Bounding boxes for weakly-supervised breast cancer segmentation in DCE-MRI
    Zhong, Yuming
    Xu, Zeyan
    Han, Chu
    Liu, Zaiyi
    Wang, Yi
    BIOMEDICAL SIGNAL PROCESSING AND CONTROL, 2025, 105
  • [23] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [24] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Isabel Pinhel
    Margaret Hills
    Suzanne Drury
    Janine Salter
    Georges Sumo
    Roger A'Hern
    Judith M Bliss
    Ivana Sestak
    Jack Cuzick
    Peter Barrett-Lee
    Adrian Harris
    Mitch Dowsett
    Breast Cancer Research, 14
  • [25] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [26] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Pinhel, Isabel
    Hills, Margaret
    Drury, Suzanne
    Salter, Janine
    Sumo, Georges
    A'Hern, Roger
    Bliss, Judith M.
    Sestak, Ivana
    Cuzick, Jack
    Barrett-Lee, Peter
    Harris, Adrian
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2012, 14 (02)
  • [27] Analysis of truncated HER2 expression and activation in breast cancer
    Singh, S.
    Liu, X.
    Lee, T.
    Kirkland, R.
    Kuller, A.
    Ohrmund, L.
    Lin, F.
    Hanna, M.
    Kim, P.
    Ybarrondo, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Feature Analysis of Biomarker Descriptors for HER2 Classification of Histology Slides
    Mukundan, Ramakrishnan
    MEDICAL IMAGE UNDERSTANDING AND ANALYSIS, MIUA 2018, 2018, 894 : 118 - 129
  • [29] HER2 expression occurs early in breast cancer dissemination
    Ignatiadis, Michail
    Durbecq, Virginie
    Veys, Isabelle
    Rosari, Jose
    Criscitiello, Carmen
    Bedard, Philippe
    Singhal, Sandeep K.
    Buxant, Frederic
    Chaboteaux, Carole
    Ghizlane, Rouas
    Larsimont, Denis
    Liebens, Fabienne
    Piccart, Martine
    Sotiriou, Christos
    CANCER RESEARCH, 2010, 70
  • [30] HER2 Low Expression in Primary Male Breast Cancer
    Nobbe, Katleen
    Erices-Leclercq, Melanie
    Foerster, Frank
    Forster, Robert
    Baldus, Stephan E.
    Rudlowski, Christian
    Schroeder, Lars
    Lubig, Sabine
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 141 - 148